Titlebook: Data Monitoring in Clinical Trials; A Case Studies Appro David L. DeMets,Curt D. Furberg,Lawrence M. Friedm Book 2006 Springer-Verlag New Y

hexagon

書目名稱Data Monitoring in Clinical Trials影響因子(影響力)




書目名稱Data Monitoring in Clinical Trials影響因子(影響力)學(xué)科排名




書目名稱Data Monitoring in Clinical Trials網(wǎng)絡(luò)公開度




書目名稱Data Monitoring in Clinical Trials網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Data Monitoring in Clinical Trials被引頻次




書目名稱Data Monitoring in Clinical Trials被引頻次學(xué)科排名




書目名稱Data Monitoring in Clinical Trials年度引用




書目名稱Data Monitoring in Clinical Trials年度引用學(xué)科排名




書目名稱Data Monitoring in Clinical Trials讀者反饋




書目名稱Data Monitoring in Clinical Trials讀者反饋學(xué)科排名

Urologist

Data and Safety Monitoring in the Beta-Blocker Heart Attack Trial: Early Experience in Formal Monitoarction. The primary outcome was total mortality. The trial ended nine months ahead of schedule because of clear benefit from propranolol. The independent monitoring committee considered several newly developed statistical approaches in recommending early stopping, as well as other factors, includin

作繭自縛

頭盔

Early Termination of the Stroke Prevention in Atrial Fibrillation I Trial: Protecting Participant Innts with nonvalvular atrial fibrillation. Participants were categorized as either warfarin-eligible or warfarin-ineligible based on contraindications to or refusal of anticoagulation, and interim efficacy monitoring examined treatment effects separately by warfarin eligibility. The planned primary a

消滅

的事物

Data Monitoring in the AIDS Clinical Trials Group Study #981: Conflicting Interim Results200 mg daily) with clotrimazole lozenges (10mg, five times daily) for prevention of invasive fungal infections in patients with advanced HIV disease. At the fourth DSMB review of the study in November 1992, the patients on fluconazole had a significantly lower risk of invasive, serious and superfici

的事物

Challenges in Monitoring the Breast Cancer Prevention Trialcal Breast and Bowel Project (NSABP), a National Cancer Institute (NCI)-funded cancer cooperative group. The primary hypothesis tested was whether tamoxifen, a drug that is beneficial for treatment of breast cancer, was effective in preventing the occurrence of cancer in women at increased risk. The

空氣傳播

Mortar

Stopping the Randomized Aldactone Evaluation Study Early for Efficacy of daily spironolactone to standard therapy would reduce the risk of all-cause mortality in patients with severe heart failure as a result of systolic left ventricular dysfunction. The Data Safety Monitoring Board (DSMB) for RALES reviewed data on safety and efficacy throughout the trial using pre-

Demonstrate

Data Monitoring in the Heart Outcomes Prevention Evaluation and the Clopidogrel in Unstable Angina tin the data, but also to avoid the loss of important treatment information concerning secondary outcomes, key subgroups, and patient safety data. For the Heart Outcomes Prevention Evaluation (HOPE) and Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trials, their Data and